Search PubMed⌕ Search

Biomedical subjects

T Tursz

Publications and source records attributed to T Tursz.

At least 163 records · Page 9Linked to original sources
PubMed1985

Induction of cell differentiation in Burkitt lymphoma lines. BLA: a glycolipid marker of B-cell differentiation.

We have previously described an MAb referred to as 38.13 which reacts with a glycolipid membrane antigen (named BLA) on Burkitt lymphoma (BL) lines. The BLA antigen and other B-cell differentiation markers have been studied on BL lines treated with sodium butyrate, agents from the phorbol-diester series (with or without differentiating properties) and teleocidin. With all differentiation inducers tested, expression of BLA as well as of surface IgM decreased on the induced cells whereas that of BI increased and that of HLA DR remained stable. No BL cells studied reacted with anti-IgD, with B2 or with LBI MAbs, either before or after induction. An EBV-negative line (BJAB) was compared to its Epstein-Barr virus (EBV)-converted subline (BJAB/B95). Both EBV-positive and EBV-negative lines gave comparable results. These data demonstrate that BL cells could be moved along their differentiation pathway by chemical inducers and suggest that BLA represents a new glycolipid marker of early B-cell differentiation.

Antibodies, Monoclonal↗
PubMed1985

[Natural killer lymphocytes. Their role in pathology].

Natural killer lymphocytes can spontaneously kill in vitro a variety of malignant cultured cells. NK cells are present in all normal individuals, and in some species (human, rats) present peculiar morphological features (large granular lymphocytes). They are usually lacking conventional T or B markers, but it appears likely that most NK cells actually are poorly mature cells belonging to the T cell lineage. The physiological control of NK activity is complex. A major role seems to be devoted to the production of interferon. The physiological roles of NK cells are still unknown: they might participate in the control of cell differentiation, in peculiar of hematopoietic precursors and thymocytes; they probably play a role as defense mechanisms during the first days of viral infections; they might be involved in bone-marrow allograft rejection and in acute graft-versus-host disease. However, their actual role in anti-tumor surveillance remains controversial, especially in humans. Nevertheless, NK cells might play some role in the surveillance against leukemias and lymphomas. NK cell defects could participate in the increased occurrence of lymphoproliferative disorders observed in immuno-suppressed patients.

Animals↗
PubMed1985

Accessory function of human leukemic cell lines: properties of B and B-K562 hybrid cell lines.

The accessory function (AF) of various B cell lines has been investigated by studying their ability to replace monocytes inducing the proliferation of highly purified T lymphocytes in the presence of phytohemagglutinin. AF could be exerted by B cells from different origin, including Epstein-Barr virus (EBV) transformed lymphoblastoid cell lines (LCL), Burkitt's lymphoma (BL)-derived lines, either EBV-positive or not, pre-B and B leukemias and lymphomas. The EBV-converted BJAB-B95 BL cells could exert an AF as efficient as BJAB cells, their EBV-negative counterparts, which demonstrates that EBV itself does not play any role in this function. The HLA-DR antigen-negative BL-K562 hybrids PUTKO and DUTKO, T51.4.1.6 cells which derived from an HLA-DR-negative variant of the T51 LCL and 721.84.5 cells from a mutagenically dissected HLA-DR-negative clone of the 721 LCL, also exerted very efficient AF. 721 LCL, PUTKO and DUTKO hybrids could produce interleukin 1 activity when triggered with 12-O-tetradecanoyl-phorbol 13-acetate (TPA). Furthermore, addition of anti-DR monoclonal antibodies which blocked completely the AF of the B cell lines in mixed lymphocyte-tumor cell reaction did not affect the mitogen-triggered AF exerted by the same B cell lines. The induction of cellular differentiation with TPA markedly reduced the AF exerted by all B cell lines studied as well as by the hybrid cells DUTKO. By contrast, the PUTKO hybrid was unsensitive to sodium butyrate and TPA treatments, which were unable to abrogate its AF. Taken together, these data indicate that the AF in mitogen-induced T lymphocyte responses is dependent upon some precise maturational stages of accessory cells and HLA-DR antigen expression is not required for AF in mitogen-induced proliferation assays.

Animals↗
PubMed1985

A monoclonal antibody against a Burkitt lymphoma associated antigen has an anti-Pk red blood cell specificity.

The blood group specificity of a rat IgM monoclonal antibody (38-13) directed against most EBV-positive or -negative Burkitt's lymphoma was investigated. The target antigen was previously identified as the neutral glycolipid ceramide trihexoside (CTH), a substance which accumulates in red cells from very rare individuals of the Pk phenotype and which appears as a normal intermediate in the biosynthetic pathway of the P blood group antigen (globoside). The 38-13 antibody agglutinated Pk1 and Pk2 red cells at 4 degrees C with a very high titre but was inactive against native P1, P2 and p erythrocytes, although a very weak activity was noticed towards papain-treated P1 and P2 erythrocytes. These results were confirmed by an indirect radio-binding assay which also demonstrated that the 38-13 antibody reacted with lymphocytes, fibroblasts and EBV-positive lymphoblastoid cell lines derived from Pk1 and Pk2 individuals but not from other donors. These findings demonstrate that the 38-13 monoclonal antibody previously considered as specific of Burkitt cells could be routinely used as an anti-Pk blood group typing reagent. The mechanism of CTH accumulation in Burkitt cells and Pk red cells is probably different and might be associated respectively with the activation of an alpha-4-galactosyltransferase or the genetic blockage of a beta-3-N-acetylgalactosaminyltransferase.

Animals↗
PubMed1985

IL 2 receptor induction on human T lymphocytes: role for IL 2 and monocytes.

In this report we studied the requirements for the activation and proliferation of highly purified human T lymphocytes. Purified T cells incubated for 3 days with PHA neither proliferate nor express IL 2 receptors as detected by FACS analysis with the use of anti-Tac antibodies. However, purified T cells incubated with Con A or anti-T3 moAb do not proliferate, albeit 30 to 35% T cells express Tac epitopes. The addition of IL 2, either natural purified or recombinant, resulted in both the appearance of Tac antigen and the proliferation of PHA-activated T cells. Much to our surprise, IL 2 did not induce proliferation of Tac-positive T cells activated by Con A or soluble anti-T3 unless monocytes were added to the cultures. These data suggested that two classes of IL 2 receptors might exist on T cells, one of which was not functionally involved in T cell proliferation. In keeping with this interpretation, we have been able to demonstrate, using a radiolabeled IL 2 binding assay, that anti-T3 moAb induced almost exclusively IL 2 receptors of low affinity (Kd = 30 to 70 X 10(-9) M) and that additional signals, provided by monocytes, are required for the acquisition of high affinity receptors. IL 2 itself can induce high affinity receptors on PHA-stimulated T cells but not on cells activated by Con A or anti-T3. In this latter case the physical presence of monocytes is required and cannot be substituted by IL 1, thus indicating a previously unreported role for monocytes. It is postulated that the contact of monocytes with T cells induces a switch from an inactive low affinity conformation of the IL 2 receptor to a functional high affinity one.

Adult↗
PubMed1985

HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: modulation by differentiation inducers and interferon.

K562 cells, which could be regarded as pluripotent hematopoietic progenitors, are usually considered as HLA class-I and class-II-negative cells. We show here that differentiation induction (with either sodium butyrate, 12-O-tetradecanoyl-phorbol-13-acetate, or teleocidin) or recombinant alpha- or gamma-interferon (IFN) treatment resulted in the augmentation of HLA class-I antigen expression. This augmentation of HLA class-I antigens was also observed in the Burkitt X K562 hybrid cells PUTKO and DUTKO (the latter coming from two presumably HLA-A, B-negative parents). HLA class-I genes are thus functional in K562 cells. In this system, alpha- and gamma-IFN had no clear differentiating capacity, since they were not able to modulate the expression of various hematopoietic markers, as chemical differentiation inducers did. On the other hand, neither differentiation induction nor interferon treatment could induce HLA class-II antigen expression on K562 cells. These molecules could be very faintly induced in PUTKO and DUTKO hybrids, in contrast with strong HLA class-II expression on the B parental lines. Whether these results are due to "lineage infidelity" in K562 cells or whether K562 cells represent the proliferation of HLA class-I-positive class-II-negative hematopoietic cells, with active suppression of HLA class-II antigen expression, is discussed.

Burkitt Lymphoma↗
PubMed1985

38.13: a monoclonal antibody directed against a Burkitt's lymphoma-associated antigen and its use as carrier for toxins.

We have previously described a monoclonal antibody, referred to as 38.13, reacting with most Burkitt's lymphoma (BL) derived lines, both with and without Epstein-Barr virus (EBV), but not reacting with EBV-positive lymphoblastoid cell lines (Wiels et al., 1981, 1982). The antibody reacted with 41 BL lines out of 57 tested. The target antigen, BLA, was shown to be a neutral glycolipid, identified as globotriaosylceramide (Gal alpha 1----4Gal beta 1----4 Glc beta 1----1 ceramide) (Nudelman et al., 1983). This substance is known as the blood group antigen Pk, a normal intermediate in the P-substance synthesis. The 38.13 antibody was covalently linked to either ricin-A chain or gelonin toxin, and its anti-BL specificity remained unaffected. Both immunotoxins were highly cytotoxic for cultured BL cells. The kinetics of the toxic effects of the immunotoxins on these cells appeared to be strikingly fast, since 50% protein synthesis inhibition was achieved after two hours' incubation. These kinetics are similar to those obtained with entire ricin, and clearly different from those observed when using immunotoxins directed against protein antigens (16-30 h). When longer incubation times are used, killing of apparently irrelevant targets was reproducibly observed. These data suggest the presence of a low number of antigenic sites on non-Burkitt cells. The detection of a low number of antigenic sites by immunotoxins directed towards such glycolipid antigens might not be a disadvantage, but might rather permit efficient and rapid killing of a wide variety of tumour cells.

Antibodies, Monoclonal↗
PubMed1984

Enzymatic and organizational difference in expression of a Burkitt lymphoma-associated antigen (globotriaosylceramide) in Burkitt lymphoma and lymphoblastoid cell lines.

In our previous study, a Burkitt lymphoma-associated antigen defined by a monoclonal antibody, designated 38.13, was characterized as globotriaosylceramide (Gb3, Gal alpha 1----4 Gal beta 1----4 Glc beta 1----1 Cer) (Nudelman, E., Kannagi, R., Hakomori, S., Parsons, M., Lipinski, M., Wiels, J., Fellous, M., and Tursz, T. (1983) Science (Wash. D.C.) 220, 509-511). Consequently, we have studied the enzymatic basis and organization of Gb3 expression in Burkitt as compared with non-Burkitt lymphoblastoid cell lines. Burkitt lymphoma cell lines (Ramos, Daudi, Put) were characterized by a high chemical quantity of Gb3, high enzyme activity for synthesis of Gb3 (UDP-Gal:LacCer alpha-galactosyltransferase), and a high degree of surface exposure of Gb3, as determined by galactose oxidase/NaB[3H]4 and by cytofluorometry with the monoclonal antibody to Gb3 (38.13). Non-Burkitt lymphoblastoid cell lines (Priess, Remb1, and ARH77) were characterized by the absence of Gb3 at the cell surface detected by cytofluorometry or cell-surface labeling. The cell lines Priess and Remb1 did not contain Gb3 and showed a low alpha-galactosyltransferase activity for Gb3 synthesis. However, the cell line ARH77, though it did not express Gb3 at the cell surface, was found to contain a large chemical quantity of Gb3 and a high level of alpha-galactosyltransferase activity for Gb3 synthesis. However, Gb3 of ARH77 cells was exposed by sialidase treatment, but not by protease treatment, although Gb3 itself was not sialylated. The crypticity of Gb3 in ARH77 cells could be associated with an adjacent sialosyl residue of a second glycoconjugate at the cell surface, in the same way as Gg3 in mouse lymphoma L5178 (Urdal, D. L., and Hakomori, S. (1983) J. Biol. Chem. 258, 6869-6874). Thus, the expression in Burkitt and non-Burkitt lymphoma is dependent on (i) Gb3 synthesis due to alpha-galactosyltransferase activity and (ii) membrane organization of Gb3, which may be controlled through interaction with the sialosyl residue of a second glycoconjugate.

Antigens, Neoplasm↗
PubMed1984

Target structure for natural killer cells: evidence against a unique role for transferrin receptor.

The transferrin receptor (TfR) was recently proposed as putative natural killer (NK) cell target structure. Here data are presented against this hypothesis and it is shown that low TfR expression and high NK sensitivity can occur concommitantly . K562 cells were studied at various stages of cell proliferation. No change in NK sensitivity could be observed between exponential growth and the plateau phase, whereas TfR expression completely disappeared during the latter. Protein synthesis inhibitors such as cycloheximide (1 microgram/ml, 48 h) and actinomycin D (50 micrograms/ml, 48 h), that abolished the TfR expression at the K562 cell surface, had no effect on NK sensitivity. Similarly, hemin induction (0.1 mM, 5 days) did not change NK susceptibility of K562 cells but considerably diminished TfR expression. Moreover, attempts to block NK sensitivity with anti-TfR monoclonal antibodies were unsuccessful, even when the 42.6 antibody, which is known to bind to the active site of TfR, was used. Finally, no blocking of NK sensitivity could be achieved when K562 cells were preincubated with saturating concentrations of transferrin or when transferrin was added during the NK assay. It therefore seems doubtful that TfR is the unique target structure for NK cells. It remains possible that TfR and NK target structures are often coexpressed on actively dividing cells.

Antibodies, Monoclonal↗
PubMed1984

K562 cells induced to differentiate by phorbol ester tumor promotors resist NK lysis.

The effect of various phorbols and phorbol diesters on the NK sensitivity of the human leukemic K562 cells was studied. A marked decrease in K562 cell susceptibility was achieved by culture in the presence of either 12-O-tetradecanoyl-phorbol-13-acetate (TPA) or beta-phorbol-dibutyrate. The maximum protection against NK lysis was achieved when K562 cells were cultured in the presence of 160 nM TPA for 48 hr (mean percentage inhibition: 61% of specific lysis). As for untreated targets, the residual killing of K562 cells after TPA treatment was mediated through large granular lymphocytes (LGL). The experimental procedures required to achieve maximal NK protection with TPA resulted simultaneously in marked phenotypical changes in K562 cells: erythroid and early myeloid markers decreased, whereas the expression of megakaryocytic markers was increased as shown by staining with antiplatelet monoclonal antibodies and assessment of platelet peroxidase activity. Chemical phorbol analogs which were unable to induce K562 cell differentiation did not affect K562 cell sensitivity to NK lysis. De novo protein synthesis is involved in the TPA-induced NK resistance, since this effect was abolished by pretreatment of K562 cells with actinomycin D or cycloheximide. TPA has been previously demonstrated to reduce NK effector activity. In our data however, the observed TPA effects were not due to release of TPA acting on effector cells during the NK assay since TPA-treated K562 cell supernatants were unable to inhibit NK activity in control assays. Thus, TPA appears to decrease NK killing of malignant cells, both by depressing NK effector cells functions and by reducing the susceptibility to NK lysis of the target cells. In single-cell agarose assays, TPA-treated K562 cells demonstrated reduced NK-binding capacity and reduced sensitivity to lysis after binding. These defects could not be reversed by activation of the NK effector cells with interferon. The results here reported extend the previously suggested relations between the expression of NK-target structures and the differentiation stage of malignant cells.

Cell Differentiation↗
PubMed1984

Identical reactivity of monoclonal antibodies HNK-1 and NC-1: conservation in vertebrates on cells derived from the neural primordium and on some leukocytes.

NC-1 and HNK-1, two mouse monoclonal antibodies raised against quail ciliary ganglion and a human leukemic cell-line, respectively, were found to display the same pattern of reactivity. Species investigated included human, rodents, birds and amphibians. In 1- to 3-day-old avian embryos, migrating crest cells are stained, whereas in older animals neuroepithelial cells and neurons are labelled. Staining with fluorescein isothiocyanate-conjugated NC-1 is blocked by preincubation with HNK-1. In immunoblot analyses both antibodies recognize the same pattern of bands which are different in central and peripheral nervous systems and vary during development. Thus, HNK-1/NC-1 provides a useful tool for investigating the ontogeny of neural and lymphocytic cells carrying this determinant, which, in view of its high degree of conservation during vertebrate evolution, may play an important part within the haematopoietic and nervous systems.

Animals↗
PubMed1984

[A monoclonal antibody, specific for Burkitt's lymphoma, is also a blood group Pk antibody].

We have previously described a monoclonal antibody, referred to as 38.13, reacting with most Burkitt's lymphoma (BL) derived lines, either containing the Epstein-Barr virus (EBV) or not, but not reacting with EBV-positive lymphoblastoid cell lines (LCL). (PNAS 78: 6485, 1981; Int. J. Cancer 29: 653, 1982). The antibody reacted with 41 BL lines out of 57 tested so far. The target antigen. BLA, was shown to be a neutral glycolipid, identified as globotriaosylceramide (Gal alpha 1----4 Gal beta 1----4 Glc beta 1----1 Ceramide). This substance is known as Pk blood group antigen, a normal intermediate in the P substance synthesis. Pk antigen is detectable only on the erythrocytes of very rare individuals with the Pk phenotype. We showed that 38.13 antibody stained erythrocytes and fibroblasts from 2 Pk subjects, whereas it was unreactive with erythrocytes and fibroblasts of all the other individuals tested. The accumulation of globotriaosylceramide on BL cells could reflect some functional disturbance of the enzymes in the P substance synthesis pathway.

Antibodies, Monoclonal↗
PubMed1984

Accessory function and interleukin 1 production by human leukemic cell lines.

Highly purified T lymphocytes do not proliferate in response to mitogens, unless adherent HLA-DR-positive monocytes are added to the culture. This accessory function (AF) of monocytes requires the release of interleukin 1 (IL 1). Cells from three human leukemic cell lines, K562, HL60, and U937, could very efficiently replace monocytes in a 72-hr mitogen-induced T cell proliferation assay. The AF was clearly related to precise maturational stages of these cells; the hematopoietic precursor K562 cells spontaneously exerted high AF, but lost this property when treated with differentiation inducers. On the contrary, the promyelocytic HL60 cells and the "histiocytic" U937 cells exhibited no spontaneous AF, but acquired this property when induced to differentiate along the granulocytic and/or monocytic pathway. Three leukemic cells could not only stimulate T cells to proliferate and produce IL 2 in the presence of mitogens, but also under appropriate culture conditions these cells could produce IL 1, which could not be distinguished from normal human monocyte derived IL 1 by gel filtration and isoelectric focusing. Moreover, analysis of phenotypic markers revealed that AF and production of IL 1 could be demonstrated in different cell types and therefore are not restricted to the monocytic lineage. No HLA-DR antigen could be detected on K562 and HL60 cells. Thus, the expression of the DR antigens is not required for AF and IL 1 production in response to mitogens. These three human leukemic cell lines will provide convenient sources of human IL 1.

Cell Line↗
PubMed1984

Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma.

A monoclonal immunoglobulin M (IgM) antibody (38-13) which recognizes Burkitt's lymphoma (BL) cells, by reacting with the neutral glycolipid Gal alpha 1 leads to 4-Gal beta 1 leads to 4-Glc beta 1 leads to 1-ceramide, was recently characterized. This monoclonal IgM was coupled to either ricin A chain or gelonin. The two different immunotoxins obtained retained the apparent immunological specificity of 38-13 IgM, as shown by flow cytofluorometry analysis and complement-dependent cytotoxicity test. The BL Ramos cells and the apparently irrelevant Epstein-Barr virus-containing lymphoblastoid Priess cells were used as targets in in vitro assays of the cytotoxic properties of the two immunotoxins by measuring the inhibition of protein synthesis. Isolated ricin A chain, gelonin, and 38-13 IgM exhibited very low intrinsic cytotoxicity on both target cells. 38-13 ricin A chain and 38-13 gelonin conjugates exerted toxic effects on both target cells which were about 6000-fold and 3000-fold higher than uncoupled ricin A chain and gelonin, respectively. The toxicity of these conjugates almost reached that of intact ricin. On Ramos BL cells, the kinetics of action of the 38-13 ricin A chain conjugate was almost as fast as that of intact ricin, because 50% protein synthesis inhibition was reached after 3 hr. In contrast, the kinetics of action in the non-BL Priess was much slower (50% protein synthesis inhibition after 10 hr). An obviously irrelevant immunotoxin (anti-trinitrophenol IgM-ricin A chain) had no significant cytotoxic effect on BL Ramos and non-BL Priess cells. An excess of D-galactose was shown previously to inhibit the 38-13 IgM from binding to the reactive glycolipid antigen bearing a terminal galactose. An excess of D-galactose (0.1 M) inhibited the cytotoxic effect of the two 38-13 immunotoxins, whereas it did not prevent the cytotoxic effect of the anti-trinitrophenol immunotoxin on the same trinitrophenol labeled target cells. These data suggest that the cytotoxic effect observed with 38-13 immunotoxins on non-BL Priess cells was mediated through their binding to a very low number of antigenic sites undetectable by conventional immunological methods. The main characteristics of 38-13 immunotoxins appear to be their fast kinetics of action and the very low number of antigenic sites required for the expression of their toxic effects. These properties could be related to the glycolipid nature of the reacting antigen. Such glycolipid antigens would represent valuable targets for therapeutic use of immunotoxins.

Antibodies, Monoclonal↗
PubMed1983

HNK-1 antibody detects an antigen expressed on neuroectodermal cells.

The HNK-1 antibody known to define a subpopulation of human lymphocytes with natural killer and killer cell activities was shown to detect a common neuroectodermal antigen. Most tumor lines and paraffin-embedded tumors and normal tissues of neuroectodermal origin were specifically stained by HNK-1. Lines and tissues of other derivations were negative except a trophoblastic tumor line and a percentage of Ewing's sarcomas, whose histogenesis is poorly understood. These data indicate that HNK-1 antibody could be of interest in clinical histopathology but cannot be considered as specific for a lymphocyte subset.

Antibodies, Monoclonal↗
PubMed1983

Expression of the BLA antigen, defined by the monoclonal 38.13 antibody, on Burkitt lymphoma lines, lymphoblastoid cell lines, their hybrids and other B-cell lymphomas and leukemias.

The BLA expression of eight Burkitt lymphoma lines was high, whereas it was negative in four, including the two IgG producers tested. Most lymphoblastoid cell lines (LCL) of normal origin had only a low percentage of positive cells, not significantly above background, although a few had up to 30% positives. EBV conversion of the EBV-negative Burkitt lymphoma line Ramos destabilized the high BLA expression, leading to a decrease in the average number of positive cells in the majority of the converted sublines in parallel with considerable fluctuation in antigen expression within each subline. Our group has previously shown that EBV-conversion of Ramos cells can induce certain differentiation steps (Spira et al., 1981 a). EBV-converted sublines of another EBV-negative Burkitt lymphoma, BJAB, showed a much greater stability previously and remained unchanged with regard to BLA expression in our present experiments. Eight T-cell leukemias, three myeloid leukemia lines and two diffuse histiocytic lymphomas were negative for BLA, whereas two myeloma lines were 30-40% positive. A histiocytic tumor had marginal reactions. Hybrids derived from the fusion of high with low BLA-reactive parental lines showed all three possible patterns (high, intermediate and low), provided that B-cell lines were fused with each other. Fusion of two Burkitt lymphoma lines with the K562 erythroleukemia line led to the extinction of BLA expression, as well as to the eclipse of other B-cell markers. B-lymphoma and leukemia (CLL) cells harvested directly from the patient showed a heterogeneous reactivity pattern. Strong to intermediate BLA expression was found among CLL cells and in most histological groups of B-CLL lymphomas except the centroblastic group (3/3 negatives). IgG-expressing follicular lymphomas were less reactive than IgM +/- IgD lymphomas of the same group. Immunocytomas were also low-reactive. BLA can be thus expressed on a variety of B-cell neoplasms; the degree of its expression appears to be related to the stage of differentiation.

Antibodies, Monoclonal↗
PubMed1983

A glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody.

The antigen defined by a rat monoclonal antibody directed to a Burkitt lymphoma cell line was identified as globotriaosylceramide [Gal alpha (1 leads to 4)-Gal beta (1 leads to 4)-Glc beta (1 leads to 1)-ceramide]. The antibody demonstrated a strict steric specificity since it did not react with globoisotriaosylceramide [Gal alpha (1 leads to 3)-Gal beta (1 leads to 4)-Glc beta (1 leads to 1)-ceramide], the positional isomer of the antigen associated with the Burkitt lymphoma. Chemical analysis of various Burkitt lymphoma cell lines revealed that the Burkitt lymphoma cells contained more than 100 times as much of the glycolipid antigen as was found in other human lymphoma and leukemia cell lines.

Animals↗